Table 1

Patient baseline data and changes in forced expiratory volume in one second (FEV₁), forced vital capacity (FVC) and provocation dose causing a 20% fall in FEV₁ (PC₂₀; expressed as the adenosine 5′-monophosphate (AMP) doubling dose number at which FEV₁ dropped by 20%) during the various study phases. Wilcoxon tests were used to compare the study phases

Patient	Test age	FEV₁ % pred			FVC % pred			PC₂₀ AMP doubling dose			Combined symptom score
		Pre-	Onset	During	Pre-	Onset	During	Pre-	Onset	During	Pre-	Onset	During
1	9	58	61	74	73	74	85	5	4	8	23	14	7
2	6	82	94	91	95	90	102	3	6	7	44	18	8
3	10	70	73	78	82	78	81	2	5	6	30	9	10
4	10	79	82	85	89	90	92	10	10	12	11	3	0
5	8.5	90	88	100	95	90	100	8	12	12	46	12	7
6	6	89	89	94	83	86	87	7	6	6	67	29	11
7	9	62	62	68	70	66	75	2	4	5	36	11	10
8	14	82	85	87	88	92	88	5	8	5	49	20	17
9	9	73	75	77	82	80	80	3	7	7
10	13	69	72	85	74	69	82	6	5	6	23	6	0
11	6	70	90	97	60	76	87	4	4	5	18	1	2
12	14	91	85	90	99	95	98	6	6	9	25	15	3
Mean	6.5	76.3	79.7	85.5	82.5	82.2	88.0	5.1	6.4	7.5	33.8	12.5	6.8
sd	2.9	11.0	10.9	9.8	11.6	9.6	8.5	2.5	2.5	2.5	16.4	8.0	5.2
p-value			ns^#	0.005^¶		ns^#	0.004^¶		0.043^#	ns^¶		0.001^#	0.01^¶
				0.003^#			0.03^#			0.0001^#			0.001^#

Statistical analysis comparing the study phases (Wilcoxon) is shown
% pred: % predicted
ns: nonsignificant
^#: compared with the prestudy phase
^¶: compared with the onset study phase